Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sinopharm Tech Holdings Limited Capital/Financing Update 2021

Sep 17, 2021

51300_rns_2021-09-17_88cddde7-bd02-4927-8da9-bbd462e7a426.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement appears for information purpose only and does not constitute an invitation or offer to acquire, purchase or subscribe for the securities of Sinopharm Tech Holdings Limited.

==> picture [80 x 77] intentionally omitted <==

Sinopharm Tech Holdings Limited 國藥科技股份有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8156)

EXTENSION OF LONG STOP DATE OF CONNECTED TRANSACTIONS: LOAN CAPITALISATION INVOLVING ISSUE OF NEW SHARES UNDER GENERAL MANDATE AND FURTHER DELAY IN DESPATCH OF CIRCULAR

Reference is made to (i) the announcements of Sinopharm Tech Holdings Limited (the “ Company ”) dated 8 June 2021 and 24 June 2021 (the “ Announcements ”) in relation to the connected transactions: Loan Capitalisation involving issue of new Shares under General Mandate; and the Loan Capitalisation involving issue of new Shares under General Mandate; and (ii) the announcements of the Company dated 30 June 2021 and 19 August 2021 (the “ Delay Announcements ”) in relation to the delay in dispatch of circular. Unless otherwise specified, capitalised terms used herein shall have the same meanings as those defined in the Announcements.

EXTENSION OF THE LONG STOP DATE

Pursuant to the First Loan Capitalisation Agreement, the Second Loan Capitalisation Agreement and the Third Loan Capitalisation Agreement, completion is conditional upon and subject to all the conditions precedent being fulfilled or waived on or before 17 September 2021 (the “ Long Stop Date ”). On 17 September 2021, the parties to the First Loan Capitalisation Agreement, the Second Loan Capitalisation Agreement and the Third Loan Capitalisation Agreement entered into a supplemental agreement to extend the Long Stop Date to 29 October 2021 (or such later date as the parties may agree in writing). Save as aforesaid, all other terms and conditions of the First Loan Capitalisation Agreement, the Second Loan Capitalisation Agreement and the Third Loan Capitalisation Agreement shall remain unchanged.

  • 1 -

FURTHER DELAY IN DESPATCH OF CIRCULAR

As disclosed in the Delay Announcements, a circular (the “ Circular ”) containing, amongst other information, (i) further information on the Loan Capitalisation; (ii) the respective advice from the Independent Board Committee and the independent financial adviser on the terms of the First Loan Capitalisation Agreement, the Second Loan Capitalisation Agreement and the Third Loan Capitalisation Agreement and the transactions contemplated thereunder; and (iii) a notice of EGM and a form of proxy, will be despatched to the Shareholders on or before 17 September 2021.

As additional time is required for the Company to prepare and finalise certain information to be included in the Circular, it is expected that the despatch date of the Circular will be delayed to a date falling on or before 30 September 2021.

By order of the Board Sinopharm Tech Holdings Limited 國藥科技股份有限公司 CHAN Ting Chairperson

Hong Kong, 17 September 2021

As at the date of this announcement, the Board comprises Mr. CHAN Ting, Mr. LIAO Zhe and Mr. CHEUK Ka Chun Kevin as executive Directors, Madam CHEUNG Kwai Lan and Dr. CHENG Yanjie as non-executive Directors and Mr. LAU Fai Lawrence, Dr. LIU Ta-pei and Mr. CHAU Wai Wah Fred as independent non-executive Directors.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the GEM website at www.hkgem.com for a minimum period of 7 days from the date of its publication and on the website of the Company at www.sinopharmtech.com.hk.

  • 2 -